Business
INOVIO Announces the Appointment of Michael Cordera As Executive Vice President & General Counsel
PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"PLYMOUTH MEETING, Pa., March 15, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced the appointment of Michael Cordera as Executive Vice President and General Counsel. Mr. Cordera will serve on the company's executive leadership team and will report to INOVIO's President and Chief Executive Officer, Dr. J. Joseph Kim. In this role, he will be responsible for the company's legal team and strategy.\nDr. J. Joseph Kim, INOVIO's President and CEO, said, \"Michael is a seasoned legal executive with deep life sciences experience both in the US and abroad. His expertise surrounding commercial operations and global business development come at a key time for our organization. He will be a valuable leader as INOVIO executes on its plans to develop and commercialize DNA medicines to treat infectious diseases, cancer, and HPV-associated diseases.\"\nMr. Cordera joins INOVIO from Eagle Pharmaceuticals, where he served as General Counsel and Chief Compliance Officer. Before Eagle, Michael held various legal positions of increasing responsibility at Warner Chilcot and inVentiv (now Syneos) Health where he was responsible for legal affairs in North America, Europe, and Asia. Mr. Cordera began his legal career as an Associate at Sherman & Sterling, LLP. He holds a J.D. from the Rutgers School of Law and an undergraduate degree from the American University of Paris. \nAbout INOVIO's DNA Medicines Platform\nINOVIO has 15 DNA medicine clinical programs currently in development focused on HPV-associated diseases, cancer, and infectious diseases, including coronaviruses associated with COVID-19 and MERS, for which programs are being developed with funding support from the U.S. Department of Defense and the Coalition for Epidemic Preparedness Innovations (CEPI). DNA medicines are composed of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by a computer sequencing technology and designed to produce a specific immune response in the body.\nINOVIO's DNA medicines deliver optimized plasmids directly into cells intramuscularly or intradermally using INOVIO's proprietary hand-held smart device called CELLECTRA®. The CELLECTRA® device uses a b...